SG11201809725TA - Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist - Google Patents

Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist

Info

Publication number
SG11201809725TA
SG11201809725TA SG11201809725TA SG11201809725TA SG11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA
Authority
SG
Singapore
Prior art keywords
road
serene
avenue
international
banjara
Prior art date
Application number
SG11201809725TA
Inventor
Ramakrishna Nirogi
Anil Karbhari Shinde
Pradeep Jayarajan
Gopinadh Bhyrapuneni
Ramasastri Kambhampati
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of SG11201809725TA publication Critical patent/SG11201809725TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/199072 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hy- A61K 31/13 (2006.01) A61P 25/28 (2006.01) derabad, Telangana 500034 (IN). A61K 31/496 (2006.01) (74) Agent: BHASIN, Gayatri et al.; Central Square, Suite - (21) International Application Number: 328, Plaza III, 20 Manoharlal Khurana Marg, Bara Hindu PCT/IB2016/054674 Rao (off Rani Jhansi Road), Delhi 110 006 (IN). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 03 August 2016 (03.08.2016) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (26) Publication Language: English EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, (30) Priority Data: LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, 201641017203 18 May 2016 (18.05.2016) IN MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, (71) Applicant: SUVEN LIFE SCIENCES LIMITED PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, [IN/IN]; Serene Chambers, Road-5, Avenue — 7, Banjara SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, Hills, Hyderabad, Telangana 500034 (IN). UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: NIROGI, Ramakrishna; Serene Chambers, (84) Designated States (unless otherwise indicated, for every Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telangana kind of regional protection available): ARIPO (BW, GH, _ 500034 (IN). SHINDE, Anil Karbhari; Serene Cham- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, bers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telan- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, gana 500034 (IN). JAYARAJAN, Pradeep; Serene Cham- TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = bers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, Telan- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = gana 500034 (IN). BHYRAPUNENI, Gopinadh; Serene MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, _ Chambers, Road-5, Avenue — 7, Banjara Hills, Hyderabad, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = Telangana 500034 (IN). KAMBHAMPATI, Ramasastri; KM, ML, MR, NE, SN, TD, TG). Serene Chambers, Road-5, Avenue — 7, Banjara Hills, Hy- _ derabad, Telangana 500034 (IN). JASTI, Venkateswarlu; = = (54) Title: COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST = = — Figure la = = 0.8- a) -cs c 0.7- ._ a) - = = = > = 2 0.6- = ._ — E '= c.) 0.5- co in _ = 0.4 — Vehicle Compound 1 Vehicle Compound 1 Il 2 m L/kg, p.o. 1 mg/kg, p.o. 2 mL/kg, p.o. 1 mg/kg, p.o. Vehicle Vehicle Memantine, Memantine, el IN 2 m L/kg, p.o. 2 mL/kg, p.o. 0.3 mg/kg, p.o. 0.3 mg/kg, p.o. © Dala represents Mean ± SEM of discriminative index. *p<0.05 Vs vehicle (Kruskal-Wallis 0\ 0\ followed by Dunn's Multiple Comparison Tesl) N=8-11 1-1 IN 1-1 (57) : The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in C:::: ) combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further el relates to the pharmaceutical composition containing the said combination. [Continued on next page] WO 2017/199072 Al MIDEDIMOMMIDIRMEMMICHIMONMOIIIMEMOE# Declarations under Rule 4.17: — as to applicant's entitlement to apply patent (Rule 4.17(H)) for and be granted a Published: — with international search report (Art. 21(3))
SG11201809725TA 2016-05-18 2016-08-03 Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist SG11201809725TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641017203 2016-05-18
PCT/IB2016/054674 WO2017199072A1 (en) 2016-05-18 2016-08-03 Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist

Publications (1)

Publication Number Publication Date
SG11201809725TA true SG11201809725TA (en) 2018-12-28

Family

ID=56940099

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809725TA SG11201809725TA (en) 2016-05-18 2016-08-03 Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist

Country Status (19)

Country Link
US (1) US11116764B2 (en)
EP (1) EP3458040B1 (en)
JP (1) JP6606298B2 (en)
KR (1) KR102023748B1 (en)
CN (1) CN109069449A (en)
AU (1) AU2016407428B2 (en)
BR (1) BR112018073396A2 (en)
CA (1) CA3023828C (en)
DK (1) DK3458040T3 (en)
EA (1) EA036301B1 (en)
HK (1) HK1258023A1 (en)
HR (1) HRP20210640T1 (en)
HU (1) HUE055083T2 (en)
IL (1) IL262816B (en)
MX (1) MX2018013969A (en)
NZ (1) NZ747778A (en)
SG (1) SG11201809725TA (en)
WO (1) WO2017199072A1 (en)
ZA (1) ZA201807311B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102508303B1 (en) * 2017-07-03 2023-03-09 수벤 라이프 사이언시스 리미티드 Novel uses of pure 5-HT6 receptor antagonists
MX2022006535A (en) * 2019-12-02 2022-09-09 Suven Life Sciences Ltd Treating behavioral and psychological symptoms in dementia patients.
CN114761008B (en) * 2019-12-02 2024-07-19 苏文生命科学有限公司 Method for treating behavioral and psychological symptoms in patients suffering from dementia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1581492T1 (en) * 2002-11-28 2008-12-31 Suven Life Sciences Ltd N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
BR112016010788B1 (en) 2013-12-02 2023-03-21 Suven Life Sciences Limited PROCESS FOR THE LARGE-SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE

Also Published As

Publication number Publication date
EP3458040B1 (en) 2021-01-27
KR102023748B1 (en) 2019-09-20
IL262816A (en) 2018-12-31
IL262816B (en) 2020-05-31
BR112018073396A2 (en) 2019-03-19
NZ747778A (en) 2020-03-27
DK3458040T3 (en) 2021-05-03
HUE055083T2 (en) 2021-10-28
HRP20210640T1 (en) 2021-06-25
JP6606298B2 (en) 2019-11-13
US11116764B2 (en) 2021-09-14
EA201892583A1 (en) 2019-04-30
CN109069449A (en) 2018-12-21
ZA201807311B (en) 2020-01-29
AU2016407428A1 (en) 2018-11-29
WO2017199072A1 (en) 2017-11-23
CA3023828C (en) 2019-08-27
AU2016407428B2 (en) 2019-11-21
EP3458040A1 (en) 2019-03-27
HK1258023A1 (en) 2019-11-01
US20190175586A1 (en) 2019-06-13
CA3023828A1 (en) 2017-11-23
MX2018013969A (en) 2019-03-21
EA036301B1 (en) 2020-10-23
KR20180136566A (en) 2018-12-24
JP2019516696A (en) 2019-06-20

Similar Documents

Publication Publication Date Title
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201901525XA (en) Muscarinic m1 receptor positive allosteric modulators
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408140QA (en) Crystalline forms of an androgen receptor modulator
SG11201810352XA (en) New antibacterial compounds
SG11201809751XA (en) Egfr inhibitor compounds
SG11201809470RA (en) Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201407988UA (en) Process for improved opioid synthesis
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201806424TA (en) Therapeutic compounds
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201906767XA (en) Estrogen receptor modulators
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201910043PA (en) Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof